Open AccessTiotropium HandiHaler® in the treatment of COPD: A safety review
Author(s) -
Steven Kesten
Publication year - 2009
Publication title -
international journal of copd
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.394
H-Index - 67
eISSN - 1178-2005
pISSN - 1176-9106
DOI - 10.2147/copd.s4802
Subject(s) - medicine , copd , anticholinergic , tiotropium bromide , adverse effect , placebo , confidence interval , anesthesia , anticholinergic agents , clinical endpoint , randomized controlled trial , lung , lung function , alternative medicine , pathology
Tiotropium is a long-acting inhaled anticholinergic developed for the treatment of chronic obstructive pulmonary disease (COPD) and has been available since 2002. We sought to update an evaluation of the safety of tiotropium in the HandiHaler formulation as significant clinical trial data have become available over time.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom